Group 1 - The core viewpoint of the article is that China National Pharmaceutical Group (国药控股) has announced a significant expected increase in net profit for its subsidiary, China National Pharmaceutical Group Co., Ltd. (国药一致), for the fiscal year 2025 [1] - The company anticipates a net profit attributable to shareholders of the listed company to be between 1.055 billion to 1.215 billion yuan, representing a year-on-year growth of 64.20% to 89.11% [1] - The expected net profit after deducting non-recurring gains and losses is projected to be between 996 million to 1.156 billion yuan, indicating an increase of 71.38% to 98.91% year-on-year [1]

Core Viewpoint - The company, China National Pharmaceutical Group (国药控股), announced that its subsidiary, China National Pharmaceutical Group Co., Ltd. (国药一致), expects a significant increase in net profit for the fiscal year 2025, despite anticipated asset impairment losses [1] Financial Performance - The company forecasts a net profit attributable to shareholders ranging from 1.055 billion to 1.215 billion yuan for 2025, representing a year-on-year growth of 64.20% to 89.11% [1] - The expected net profit, excluding non-recurring gains and losses, is projected to be between 996 million and 1.156 billion yuan, indicating an increase of 71.38% to 98.91% compared to the previous year [1] Asset Impairment - The company plans to recognize goodwill and intangible asset impairment losses between 240 million and 330 million yuan for 2025, which is a decrease of 639.9 million to 729.9 million yuan from the previous year [1] Strategic Direction - The company aims to continue its strategic transformation and refined management practices to consolidate operational results and enhance core competitiveness, focusing on sustainable and high-quality development [1]

2025年度业绩预告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 重要提示： ● 预计2025年度实现归属于上市公司股东的净利润105,500万元到121,500万元，同比增长64.20%到 89.11%。 登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：000028、200028 证券简称：国药一致、一致B 公告编号：2026-01 国药集团一致药业股份有限公司 ● 预计2025年度实现归属于上市公司股东的扣除非经常性损益的净利润99,600万元到115,600万元，同比 增长71.38%到98.91%。 一、本期业绩预计情况 （一）业绩预告期间：2025年1月1日至2025年12月31日。 （二）业绩预告情况：预计净利润为正值且属于同向上升50%以上情形 ■ 二、与会计师事务所沟通情况 国药一致（简称"公司"）就业绩预告有关事项已与会计师事务所进行预沟通，公司与会计师事务所在业 绩预告方面不存在分歧。本次业绩预告相关的财务数据是公司财务部门初步估算得出，未经会计师事务 所审计。 三、业绩变动原因说明 2025年度，在行业政策复杂多变，市场竞 ...

（编辑 丛可心） 证券日报网讯 1月25日，国药一致发布公告称，公司预计2025年度实现归属于上市公司股东的净利润 105，500万元到121，500万元，同比增长64.20%到89.11%；预计2025年度实现归属于上市公司股东的 扣除非经常性损益的净利润99，600万元到115，600万元，同比增长71.38%到98.91%。 ...

Core Viewpoint - China National Pharmaceutical Group Corporation (国药一致) forecasts a net profit attributable to shareholders of 1.055 billion to 1.215 billion yuan for 2025, representing a year-on-year growth of 64.2% to 89.11% [1] Group 1 - The company aims to continue its strategic transformation and refined management to further consolidate operational results [1] - The focus is on enhancing core competitiveness and achieving sustainable, high-quality development [1]

Core Viewpoint - The company, China National Pharmaceutical Group Corporation (国药一致), expects a significant increase in net profit for the fiscal year 2025, indicating strong resilience and operational vitality despite a challenging market environment [1] Financial Performance - The company anticipates a net profit attributable to shareholders ranging from 1,055 million to 1,215 million yuan for 2025, representing a year-on-year growth of 64.20% to 89.11% [1] - The expected net profit, excluding non-recurring gains and losses, is projected to be between 996 million and 1,156 million yuan, with a year-on-year increase of 71.38% to 98.91% [1] Operational Strategy - In a complex and competitive industry landscape, the company demonstrates strong development resilience through proactive structural adjustments and cost management, effectively curbing profit decline and achieving overall performance recovery [1] - The distribution business remains a cornerstone of the company's operations, continuing to show stable growth [1] - The company enhances operational quality by strengthening its procurement system, optimizing product structure, and strategically adjusting store layouts [1]

南财智讯1月25日电，国药一致发布年度业绩预告，预计2025年全年归属于上市公司股东的净利润为 105500万元—121500万元，同比预增64.20%—89.11%；预计2025年全年归属于上市公司股东的扣除非 经常性损益的净利润为99600万元—115600万元，同比预增71.38%—98.91%；2025年度，在行业政策复 杂多变，市场竞争日趋激烈的环境下，公司仍展现出较强的发展韧性与经营活力，通过主动的结构调整 与成本费用管控，有效遏制了利润下滑趋势，实现整体业绩恢复增长。其中，分销业态作为公司经营的 基石，继续保持稳定增长，国大药房通过强化商采体系，优化产品结构，战略性调整门店布局，有效提 升经营质量。公司结合实际经营情况，基于谨慎性原则，经第三方专业评估机构初步评估和测算，预计 2025年度计提商誉及无形资产减值准备24000万元—33000万元，较上年同期减少63992.83万元— 72992.83万元。尽管有前述资产减值的影响，公司仍然实现归属于上市公司股东的净利润同比增长 64.20%至89.11%。 ...

Core Viewpoint - The company, China National Pharmaceutical Group Corporation (国药一致), forecasts a net profit attributable to shareholders of 1.055 billion to 1.215 billion yuan for 2025, representing a year-on-year growth of 64.20% to 89.11% [1] Group 1: Financial Performance - The expected net profit for 2025 is projected to be between 1.055 billion and 1.215 billion yuan [1] - This forecast indicates a significant increase in profitability, with a growth rate ranging from 64.20% to 89.11% compared to the previous year [1] Group 2: Business Operations - The distribution business remains a cornerstone of the company's operations, continuing to show stable growth [1] - The company has enhanced its procurement system, optimized product structure, and strategically adjusted store layouts to effectively improve operational quality [1]

（文章来源：每日经济新闻） 每经AI快讯，1月25日，国药一致公告，预计2025年度实现归属于上市公司股东的净利润10.55亿元到 12.15亿元，同比增长64.20%到89.11%。预计2025年度实现归属于上市公司股东的扣除非经常性损益的 净利润9.96亿元到11.56亿元，同比增长71.38%到98.91%。 ...

证券代码：000028、200028 证券简称：国药一致、一致 B 公告编号：2026-02 国药集团一致药业股份有限公司 1. 审议了《关于国药一致经营层成员 2025 年度考核事项的议案》 表决结果：关联董事李进雄已回避表决，8 票同意，0 票反对，0 票弃权。 该事项已经第十届董事会薪酬与考核委员会审议通过。 2. 审议通过了《关于其他应收款坏账损失核销的议案》 表决结果：9 票同意，0 票反对，0 票弃权。 第十届董事会 2026 年第一次临时会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 一、董事会会议召开情况 国药集团一致药业股份有限公司（以下简称"公司"或"国药一致"） 第十届董 事会2026年第一次临时会议于2026年1月16日以电子邮件方式发出通知和文件材料，会 议于2026年1月22日以通讯表决方式召开。应参加会议董事9名，亲自出席会议董事9名。 会议召开程序符合《公司法》、《公司章程》的有关规定。 二、董事会会议审议情况 国药集团一致药业股份有限公司董事会 2026 年 1 月 26 日 董事会同意对国药一致下属企业广东南方 ...